DDInter1042 DDInter1467
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized, placebo-controlled, parallel-group study.[L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous breakthrough designation.
Pimavanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pimavanserin may lead to a major life threatening interaction when taken with Toremifene
Pimavanserin may lead to a major life threatening interaction when taken with Vemurafenib